Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α

19 Jul 2019

Abstract excerpt

Sorafenib resistance is one of the main obstacles to the treatment of advanced/recurrent hepatocellular carcinoma (HCC). Here, sorafenib-resistant HCC cells and xenografts in nude mice were used as experimental models. A cohort of patients with advanced recurrent HCC who were receiving sorafenib therapy was used to assess the clinical significance of this therapy. Our data showed that 14-3-3η maintained sorafenib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 14-3-3 protein interactions
Share to Peptidase Inhibition and Analysis
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31341646
DOI: 10.1038/s41420-019-0200-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1αPMID 31341646Read ↗

MicroRNA-140-5p Suppresses The PD-L1 Level In Exosomes Derived From Hepatocellular Carcinoma Cells, Thereby Attenuating The Chemoresistance, Autophagy And Stemness Induced By Sorafenib In Hepatocellular CarcinomaSemantic proximity Read ↗

Loss of miR-16-1-3p Activity Predicts Chemoresistance and Progression in Osteosarcoma: An Integrative Clinicopathologic StudySemantic proximity Read ↗

Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes‐Associated Protein 1 Activation and Transient Expansion of Stem‐Like Cancer CellsSemantic proximity Read ↗

Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagySemantic proximity Read ↗

The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinomaSemantic proximity Read ↗

PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cellsSemantic proximity Read ↗

Exosomal CircRNA-MANBA Mediates Hepatocellular Carcinoma Sorafenib Resistance via miR-1290/CD109/p-STAT3 AxisSemantic proximity Read ↗

HBx Facilitates Drug Resistance in Hepatocellular Carcinoma via CD133-regulated Self-renewal of Liver Cancer Stem CellsSemantic proximity Read ↗

CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.Semantic proximity Read ↗

LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma CellsSemantic proximity Read ↗

The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.Semantic proximity Read ↗

Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.